News & Events

The value of our clients' news is directly related to the macro events and trends shaping the life sciences and healthcare industry. To appreciate one, you must fully understand the other.

Tiberend Strategic Advisors invites those interested in our firm and the companies we represent to access our News Feed and register for our Events Calendar.  Doing so, you will be assured to receive actionable information on the companies and trends that are defining the life sciences and healthcare space.

News Feed


Events Calendar

Oct 4 2017

Presentations at ID Week™ 2017 Highlight Clinical Results and Microbiome Analysis of Patients Treated in Rebiotix RBX2660 Phase 2 Studies


Oct 4 2017

KemPharm and Genco Sciences Announce Technology Licensing Agreement to Develop Prodrug-Based Therapy for Potential Rare Pediatric Indications of Tourette’s Syndrome with ADHD

Oct 3 2017

Ehave Highlights Solutions to Support and Improve ADHD Treatment During ADHD Awareness Month


Sept 25 2017

CorMedix Relocates Corporate Headquarters


Sept 21 2017

Provention Bio Announces Licensing Agreements with Janssen for Two Clinical-Stage Immunology Assets

Sept 20 2017

Ehave Announces Launch of the Next Generation of the Ehave Platform and Ehave Connect to Facilitate Rapid Third-Party Content Integration


Aug 23 2017

Rebiotix to Present at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference


Aug 17 2017

CorMedix, Inc. Awarded NIH Grant to Develop Advanced Antimicrobial Hydrogels for the Treatment and Prevention of Potentially Life-Threatening Infections in Severe Burns

Aug 15 2017

Publication in EMBO Molecular Medicine Demonstrates CureVac’s Proprietary mRNA Technology Enables Antibody Mediated Therapies Against Infectious Agents, Toxins and Tumors


June 13 2017

CureVac Extends Global Intellectual Property Estate for Prophylactic mRNA Vaccines


June 13 2017

Enteris BioPharma to Present at BIO 2017

June 9 2017

KemPharm to Present Clinical Data for KP511, an Opioid Prodrug Candidate, at the International Conference on Opioids


June 7 2017

Ehave to Present at 2017 BIO International Convention


June 7 2017

Rebiotix Data Presented at ASM Microbe 2017 Show RBX2660 Treated Patients’ Clinical Success Correlates with Improved Microbiome Diversity

June 1 2017

Rebiotix’s Phase 3 Ready RBX2660 to be Featured in Multiple Sessions at Digestive Disease Week 2017

June 1 2017

KemPharm Announces Addition to Leadership Team


May 10 2017

KemPharm, Inc. Reports First Quarter 2017 Results


May 10 2017

CorMedix Inc. Reports First Quarter Financial Results and Provides Business Update

May 10 2017

Galena Biopharma Reports First Quarter 2017 Financial Results


May 9 2017

CorMedix Inc. Demonstrates Sensitivity of Emerging Global Health Threat Candida auris to Taurolidine


May 5 2017

CorMedix Inc. to Report First Quarter 2017 Financial Results and Provide Business Update

May 4 2017

Rebiotix’s Phase 3 Ready RBX2660 to be Featured in Multiple Sessions at Digestive Disease Week 2017

May 4 2017

CorMedix Inc. Announces Closing of Public Offering of Common Stock and Warrants and Underwriter’s Exercise in Full of Over-Allotment Option


May 2 2017

CureVac Appoints Daniel Menichella as CEO of CureVac Inc., the Company’s US Subsidiary

May 1 2017

Cantex Pharmaceuticals, Inc. Announces Initiation of Phase II Clinical Development for CX-02 in Recurrent Glioblastoma

April 28 2017

CorMedix Inc. Increases Previously Announced Public Offering to $12.1 Million


April 27 2017

CorMedix Inc. Announces $10 Million Underwritten Public Offering

Apr 20 2017

CorMedix Inc. Reports Update on Neutrolin® Phase 3 LOCK-IT 100 Clinical Trial


April 19 2017

Cantex Pharmaceuticals to Present Overview of CX-02 at the World Orphan Drug Congress

Apr 12 2017

CorMedix Inc. Secures First European Commercial Collaboration for Neutrolin


Apr 11 2017

Rebiotix Reports Positive Top Line Data from Open-Label Phase 2 Trial of RBX2660 in Recurrent Clostridium difficile

Apr 7 2017

Lakewood-Amedex Advances Novel Bisphosphocin® Nu-8 Compound Based on Encouraging Pre-Clinical Results


Apr 4 2017

Cantex Pharmaceuticals, Inc. Announces Poster Presentation at AACR Annual Meeting 2017


Apr 4 2017

Galena Biopharma Presents Positive Interim Safety Data on the NeuVax™ (nelipepimut-S) Clinical Trial in Combination with Trastuzumab in High-Risk HER2 3+ Patients at the AACR Annual Meeting 2017

Mar 30 2017

Promentis Pharmaceuticals, Inc. Announces $26M Series C Financing and Elects Four New Board Members

Mar 30 2017

Enteris to Present at BioCentury’s Future Leaders


Mar 28 2017

Ehave Announces the Appointment of Dave Goyette as Chief Technology Officer

Mar 27 2017

KemPharm to Present at the 2nd Annual Neuroscience Biopartnering and Investment Forum

Mar 26 2017

Lakewood-Amedex Announces appointment of Chief Medical Officer and Chief Scientific Officer to enhance drug development and clinical trials program


Mar 22 2017

TapImmune to Participate in Two Upcoming Investor and Industry Conferences

Mar 21 2017

EnGeneIC Doses First Patient in U.S. Phase 1 Clinical Study of Targeted EDV™ Nanocells in Recurrent Glioblastoma Multiforme


Mar 17 2017

CorMedix Inc. Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update


Mar 17 2017

Galena Biopharma Presents Positive Final GALE-301 (E39) Phase 1/2a Clinical Trial Data

Mar 16 2017

KemPharm Presents Clinical Data for Opioid Prodrug Candidates at American Academy of Pain Medicine’s Annual Meeting


Mar 15 2017

Galena Biopharma Reports Fourth Quarter and Year End 2016 Financial Results and Provides a Corporate Update


Mar 14 2017

TapImmune Provides Year End 2016 Corporate and Clinical Update

Mar 9 2017

KemPharm, Inc. Reports Fourth Quarter and Year End 2016 Results

Mar 2 2017

EnGeneIC Receives FDA Orphan Drug Designation for Targeted EDV™ Nanocells to Treat Glioblastoma Multiforme


Mar 2 2017

CorMedix Inc. Appoints John L. (Jack) Armstrong to Senior Leadership Team

Mar 2 2017

Rebiotix to Present at Two Investor Conferences

View more client news »